In “How to Reframe Strategy and Compete on Outcomes,” John Singer, Global Head of Health Industry Strategy, Innovation and Technology at Wipro, elaborates on why Medical Affairs need to drive “big design” thinking to create value in the new outcomes-based healthcare world.
Here we decode self-awareness – the best approach to self-analysis to avoid being trapped looking in the rear-view mirror – and how to find and fix your blindspots.
In My Journey: The Rise & Rise of Medical, Dr. Ameet Nathwani discusses the need to define and measure our contribution, and why we need to join together as a community to shape the future of healthcare.
In “Digital Health: The Road Ahead for Medical Affairs,” CMO and Head of Medical Affairs & Pharmacovigilance at Bayer, Mike Devoy discusses Medical Affairs’ unique understanding of how value can be created and delivered, and the key role it plays in developing the evidence and solutions around that value in collaboration with internal and external partners.
This series will provide you with tools to critically process and analyze medical scientific literature. You will get a good understanding of basic statistical concepts and theory that enable you to explain, understand and interpret data. These Webinars are practical and based on published articles and the analysis of these. You will work with the theory in practice to increase your understanding of the strengths and weaknesses of the statistics in scientific literature.
Statistical analysis in clinical trials
– Null/alternative hypotheses
– Statistical assumptions (type I error, significance level, type II error, statistical power,)
– Hypothesis testing
– Statistical tests
Statistics used in RCTs
– Type of outcome measures (dichotomous, continuous, time-to-event)
– Statistics used for analysis of dichotomous data (relative risk, odds ratio, risk difference, NNT)
– Analysis of time-to-event variables (plotting and interpretation of Kaplan-Meier curves)
Early Access includes a variety of programs by which pharmaceutical companies make investigational therapies available to patients with life-threatening diseases. These patients have either exhausted available treatments or have no approved options. This presentation will review the processes and procedures to consider in the implementation of an Early Access Program and explore the opportunities and challenges posed therein.
At the end of this webinar the participant will be able to:
At the conclusion of this eCademy Webinar, participants will be better able to understand:
As healthcare continues to transform, we need to stay connected to our customers in many ways. From Upstream scientific exchange driving research, to clinical trial design establishing evidence, to co-creation workshops establishing value propositions, to education and post-release support to drive adoption, collaboration with customers across the solution lifecycle is key to providing the best solutions to our customers. MSLs are becoming more important and playing key roles across the lifecycle in partnership with many others who play important roles. We will describe the landscape, drivers, and opportunities for engaging with customers across the lifecycle and how we socialize learnings across the organization.
The Scientific Communication Platform (SCP) is the foundation of a strong medical communications strategy for a pharmaceutical product or device, and serves as an important tool to align communications and messaging across functional areas. Even minor discrepancies in cited data and/or the way that data are described can lead to confusion and weaken a product’s overall value proposition. The SCP is based on scientific evidence and requires an in-depth analysis and review of available and anticipated data, the disease and competitive landscape, stakeholder perceptions, and aspirations about the product profile. Since the final SCP output ensures accurate and consistent language and referencing through all communication activities, putting a plan in place to ensure successful cross-functional and regional implementation and utilization of this valuable resource is critical.
After completing this Webinar, participants will be better able to:
This series will provide you with tools to critically process and analyze medical scientific literature. You will get a good understanding of basic statistical concepts and theory that enable you to explain, understand and interpret data. These Webinars are practical and based on published articles and the analysis of these. You will work with the theory in practice to increase your understanding of the strengths and weaknesses of the statistics in scientific literature.